Valuation: argenx SE

Market Cap 52.87B 45.67B 42.91B 39.03B 73.37B 5,056B 74.58B 503B 197B 2,532B 199B 194B 8,413B P/E 2026 *
30.3x
P/E 2027 * 24.4x
Enterprise Value 47.46B 40.99B 38.52B 35.03B 65.86B 4,538B 66.94B 451B 176B 2,273B 178B 174B 7,552B EV / Sales 2026 *
7.64x
EV / Sales 2027 * 5.9x
Free-Float
99.98%
Yield 2026 *
0.05%
Yield 2027 * 0.09%
1 day-3.21%
1 week-4.32%
Current month-1.99%
1 month-4.07%
3 months+5.19%
6 months+3.02%
Current year+1.87%
1 week 723.4
Extreme 723.4
768.6
1 month 717.4
Extreme 717.4
829.2
Current year 568.4
Extreme 568.4
833.6
1 year 556.2
Extreme 556.2
833.6
3 years 271
Extreme 271
833.6
5 years 224.1
Extreme 224.1
833.6
10 years 12.5
Extreme 12.5
833.6
Manager TitleAgeSince
Chief Executive Officer 47 2026-05-05
Director of Finance/CFO 56 2021-05-31
Chief Tech/Sci/R&D Officer - 2014-12-31
Director TitleAgeSince
Chairman 54 2026-05-05
Director/Board Member 76 2015-05-12
Director/Board Member 65 2016-04-27
Date Insider Type Main position Quantity % Market Cap.
11/23/25 Sell

Chief Executive Officer

2,000 0.0032%
11/23/25 Sell

Director

4,680 0.0076%
11/23/25 Fiscal year

Director

4,680 0.0076%
Change 5-day change 1-year change 3-year change Capi.($)
-3.21%-4.32%+31.19%+59.75% 52.87B
-1.90%+2.85%+61.37%+102.88% 70.07B
-2.05%-5.61%-3.14%+454.89% 27.02B
-1.27%-1.57%+46.46%+6.09% 23.61B
+1.05%-0.62%-17.40%-13.36% 23.38B
+3.81%+20.97%+263.48%+552.47% 19.43B
+0.10%+1.40%+38.98%-20.04% 18.75B
-0.95%-3.52%+20.04%+613.01% 15.85B
+1.24%-5.23%+33.19%+138.21% 12.7B
+1.12%-1.25%+360.86%+194.49% 12.24B
Average -0.21%+1.63%+83.50%+208.84% 27.59B
Weighted average by Cap. -0.99%+0.47%+63.64%+169.26%

Financials

2026 *2027 *
Net sales 6.21B 5.37B 5.04B 4.59B 8.62B 594B 8.76B 59.09B 23.1B 298B 23.33B 22.82B 989B 7.64B 6.6B 6.2B 5.64B 10.6B 731B 10.78B 72.65B 28.41B 366B 28.68B 28.06B 1,216B
Net income 1.86B 1.61B 1.51B 1.38B 2.59B 178B 2.63B 17.72B 6.93B 89.25B 7B 6.85B 297B 2.47B 2.14B 2.01B 1.83B 3.43B 237B 3.49B 23.53B 9.2B 118B 9.29B 9.09B 394B
Net Debt -5.41B -4.68B -4.39B -4B -7.51B -518B -7.64B -51.48B -20.13B -259B -20.33B -19.88B -861B -7.77B -6.71B -6.31B -5.74B -10.79B -743B -10.97B -73.93B -28.91B -372B -29.19B -28.55B -1,237B
Logo argenx SE
argenx SE is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx SE aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx SE developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises.
Employees
1,863
Date Price Change Volume
26-08-14 €730.20 -3.21% 56,271
26-08-13 €754.40 -0.87% 50,123
26-08-12 €761.00 +1.60% 50,734
26-08-11 €749.00 -2.35% 91,834
26-08-10 €767.00 +0.50% 54,134
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
845.43USD
Average target price
1,229.81USD
Spread / Average Target
+45.47%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ARGX Stock